Skip to main content

Table 3 Estimated effects (crude and adjusted hazard ratios [HR] and 95% confidence intervals [CI]) of patient predictors on cinacalcet discontinuation, by type of predictor (baseline or time-dependent), in the new-user cohort (n = 613)

From: Predictors of cinacalcet discontinuation and reinitiation in hemodialysis patients: results from 7 European countries

  Baseline Time-dependent
Crude Adjusteda Crude Adjusted a
Variable HR 95% CI HR 95% CI HR 95% CI HR 95% CI
Age (yrs)
 < 45 1.20 (0.74, 1.92) 1.36 (0.81, 2.30)     
 45–54 0.78 (0.43, 1.39) 0.83 (0.46, 1.49)     
 55–64 1 (ref) 1 (ref)     
 65–74 0.97 (0.65, 1.47) 0.85 (0.52, 1.40)     
 75+ 1.48 (0.96, 2.26) 1.36 (0.83, 2.22)     
Vintage (yrs)
 < 1.0 0.78 (0.43, 1.42) 0.79 (0.44, 1.42)     
 1.0–2.9 1 (ref) 1 (ref)     
 3.0–4.9 1.16 (0.78, 1.71) 1.09 (0.74, 1.63)     
 5.0+ 0.92 (0.64, 1.33) 0.87 (0.59, 1.28)     
BMI (kg/m2)
 < 18.5 1.49 (0.75, 2.96) 1.31 (0.58, 2.97)     
 18.5–24.9 1.44 (1.01, 2.07) 1.56 (1.05, 2.30)     
 25.0–29.9 1 (ref) 1 (ref)     
 30.0+ 1.17 (0.74, 1.85) 1.30 (0.80, 2.12)     
Male sex 0.98 (0.73, 1.32) 0.94 (0.67, 1.30)     
Coronary artery disease 1.48 (1.08, 2.03) 1.26 (0.90, 1.74)     
Cancer 1.40 (0.95, 2.04) 1.31 (0.91, 1.89)     
Other cardiovascular disease 1.20 (0.80, 1.79) 1.06 (0.67, 1.68)     
Cerebrovascular disease 1.53 (1.03, 2.27) 1.39 (0.93, 2.06)     
Congestive heart failure 1.51 (1.02, 2.25) 1.21 (0.79, 1.85)     
Diabetes 0.99 (0.71, 1.38) 0.87 (0.57, 1.32)     
GI bleeding 0.94 (0.47, 1.86) 0.76 (0.33, 1.73)     
Hypertension 0.88 (0.59, 1.30) 0.77 (0.48, 1.23)     
Lung disease 1.30 (0.83, 2.03) 1.15 (0.73, 1.80)     
Psychiatric disorder 1.91 (1.29, 2.81) 1.75 (1.15, 2.66)     
Peripheral vascular disease 1.40 (1.00, 1.95) 1.24 (0.88, 1.74)     
Hospitalization in prior 3 months 1.26 (0.85, 1.87) 1.21 (0.79, 1.84) 1.58 (1.13, 2.20) 1.40 (1.01, 1.92)
Serum phosphorus (mg/dl)
 < 3.50 1.31 (0.78, 2.20) 1.39 (0.78, 2.49) 1.61 (1.11, 2.34) 1.58 (1.09, 2.30)
 3.50–5.49 1 (ref) 1 (ref) 1 (ref) 1 (ref)
 5.50–5.99 1.50 (1.02, 2.19) 1.43 (0.97, 2.11) 1.43 (0.87, 2.35) 1.36 (0.83, 2.21)
 6.00+ 0.97 (0.70, 1.35) 1.03 (0.73, 1.47) 1.05 (0.70, 1.58) 1.04 (0.69, 1.57)
Serum PTH (pg/ml)
 < 150 2.90 (1.52, 5.12) 2.26 (1.24, 4.12) 2.24 (1.39, 3.59) 2.57 (1.52, 4.33)
 150–299 1 (ref) 1 (ref) 1 (ref) 1 (ref)
 300–599 1.51 (0.90, 2.55) 1.47 (0.86, 2.52) 0.77 (0.48, 1.25) 0.84 (0.52, 1.38)
 600+ 1.60 (0.92, 2.81) 1.50 (0.85, 2.64) 0.93 (0.58, 1.50) 0.96 (0.58, 1.57)
Serum calcium (mg/dl)
 < 7.50 1.51 (0.67, 3.39) 1.43 (0.56, 3.68) 1.97 (0.89, 4.38) 1.83 (0.83, 4.04)
 7.50–8.39 1.54 (1.03, 2.31) 1.56 (0.99, 2.45) 1.68 (1.11, 2.54) 1.65 (1.04, 2.60)
 8.40–10.19 1 (ref) 1 (ref) 1 (ref) 1 (ref)
 10.20+ 0.91 (0.55, 1.50) 0.90 (0.52, 1.55) 1.06 (0.57, 1.99) 1.03 (0.52, 2.06)
Serum albumin (g/dl)
 < 3.20 0.91 (0.49, 1.67) 0.82 (0.46, 1.46) 1.26 (0.69, 2.29) 1.22 (0.69, 2.15)
 3.20–3.49 1.17 (0.74, 1.85) 1.10 (0.67, 1.80) 0.98 (0.57, 1.68) 0.96 (0.55, 1.67)
 3.50–3.79 1.14 (0.81, 1.61) 1.16 (0.81, 1.66) 1.08 (0.75, 1.54) 1.19 (0.80, 1.76)
 3.80+ 1 (ref) 1 (ref) 1 (ref) 1 (ref)
Phosphate binder use
 None 1 (ref) 1 (ref) 1 (ref) 1 (ref)
 Ca-containing only 0.60 (0.28, 1.31) 0.51 (0.25, 1.08) 0.75 (0.38, 1.51) 0.54 (0.27, 1.08)
 Non-Ca-containing only 0.97 (0.62, 1.54) 0.91 (0.58, 1.44) 1.00 (0.65, 1.56) 0.94 (0.60, 1.49)
 Both 0.97 (0.56, 1.69) 0.79 (0.45, 1.40) 0.79 (0.44, 1.40) 0.64 (0.36, 1.13)
Vitamin D use
 None 1 (ref) 1 (ref) 1 (ref) 1 (ref)
 IV vitamin D only 0.95 (0.66, 1.38) 1.00 (0.66, 1.51) 1.30 (0.91, 1.85) 1.36 (0.91, 2.03)
 Oral vitamin D only 0.76 (0.51, 1.15) 0.83 (0.56, 1.22) 1.17 (0.76, 1.79) 1.12 (0.70, 1.79)
  1. aAdjusted for baseline covariates: age, vintage, 13 summary comorbid conditions, body mass index, and male sex. Separate models estimated for each variable shown. Time-dependent effects estimated only for variables shown. Psychiatric disorder includes depression, bipolar disorder, schizophrenia, and alcohol or substance abuse